Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664928 | 1.00 | METAP1 (0.32) | METAP1ALOX5DPP4EPHX1SIGMAR1 | |
| SCHEMBL9617610 | 0.87 | — | — | |
| SCHEMBL7264712 | 0.76 | METAP2 (0.38) | METAP1 | |
| SCHEMBL7264714 | 0.76 | METAP2 (0.38) | METAP1 | |
| SCHEMBL23022847 | 0.75 | EPHX1 (0.37) | METAP1ALOX5DPP4EPHX1SIGMAR1 | |
| SCHEMBL19982043 | 0.75 | EPHX1 (0.37) | METAP1ALOX5DPP4EPHX1SIGMAR1 | |
| SCHEMBL12036058 | 0.74 | TP53 (0.35) | EPHX1 | |
| SCHEMBL19982053 | 0.72 | DPP4 (0.33) | METAP1ALOX5DPP4EPHX1 | |
| SCHEMBL5199727 | 0.72 | DPP4 (0.33) | METAP1ALOX5DPP4EPHX1 | |
| SCHEMBL453071 | 0.71 | SIGMAR1 (0.42) | METAP1ALOX5DPP4EPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2024-12-05 | — | — | US | disclosed |
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220296621-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2022-09-22 | — | — | US | disclosed |
| US-20100105753-A1 | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105629-A1 | N-Substituted Peptidomimetic Inhibitors of Dipeptidylpeptidase IV | TRUSTEES OF TUFTS COLLEGE | 2010-04-29 | — | — | US | disclosed |
| WO-2009006473-A2 | PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008128064-A2 | TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118848-A1 | N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | GEORGETOWN UNIVERSITY | 2007-11-15 | — | — | US | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | METAP1 587/4885ALOX5 1782/4885DPP4 323/4885 |
| US-20100105753-A1 | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof | FAP, FIBP, DNPEP | METAP1 32/4885ALOX5 3146/4885DPP4 166/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | METAP1 587/4885ALOX5 1782/4885DPP4 323/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | METAP1 587/4885ALOX5 1782/4885DPP4 323/4885 |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | ADH5, ADH1C, ADH1A | METAP1 1766/4885ALOX5 162/4885DPP4 3257/4885 |
| US-20220296621-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | FAP, FIBP, GOT1 | METAP1 938/4885ALOX5 1341/4885DPP4 331/4885 |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | METAP1 587/4885ALOX5 1782/4885DPP4 323/4885 |
| US-20100105629-A1 | N-Substituted Peptidomimetic Inhibitors of Dipeptidylpeptidase IV | DNPEP, DPP4, DPP3 | METAP1 23/4885ALOX5 2188/4885DPP4 2/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | METAP1 938/4885ALOX5 1341/4885DPP4 331/4885 |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | METAP1 957/4885ALOX5 1314/4885DPP4 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.